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Abstract
Purpose: Recent evidence from US claims data suggests use of high-dimensional pro-
pensity score (hd-PS) methods improve adjustment for confounding in non-
randomised studies of interventions. However, it is unclear how best to apply hd-PS
principles outside their original setting, given important differences between claims
data and electronic health records (EHRs). We aimed to implement the hd-PS in the
setting of United Kingdom (UK) EHRs.
Methods: We studied the interaction between clopidogrel and proton pump inhibi-
tors (PPIs). Whilst previous observational studies suggested an interaction (with
reduced effect of clopidogrel), case-only, genetic and randomised trial approaches
showed no interaction, strongly suggesting the original observational findings were
subject to confounding. We derived a cohort of clopidogrel users from the UK Clini-
cal Practice Research Datalink linked with the Myocardial Ischaemia National Audit
Project. Analyses estimated the hazard ratio (HR) for myocardial infarction
(MI) comparing PPI users with non-users using a Cox model adjusting for con-
founders. To reflect unique characteristics of UK EHRs, we varied the application of
hd-PS principles including the level of grouping within coding systems and adapting
the assessment of code recurrence. Results were compared with traditional analyses.
Results: Twenty-four thousand four hundred and seventy-one patients took clopidogrel,
of whom 9111 were prescribed a PPI. Traditional PS approaches obtained a HR for the
association between PPI use and MI of 1.17 (95% CI: 1.00-1.35). Applying hd-PS modifi-
cations resulted in estimates closer to the expected null (HR 1.00; 95% CI: 0.78-1.28).
Conclusions: hd-PS provided improved adjustment for confounding compared with
other approaches, suggesting hd-PS can be usefully applied in UK EHRs.
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1 | INTRODUCTION
Electronic Health Records (EHRs) are increasingly used for research
investigating the effects of medications.1,2 Adequate adjustment for
confounding remains a key issue and incorrect conclusions can be
drawn amid concerns of residual or unmeasured confounding.3,4
Developed in US claims data to improve confounder adjustment,
the high-dimensional propensity score (hd-PS) approach treats infor-
mation stored within healthcare databases as proxies for key underly-
ing confounders.5 Some proxies may be strongly correlated with
variables typically included in a traditional propensity score
(PS) analysis; others may represent information about patients that is
otherwise unmeasured, for example, frailty.5
Despite application in various settings (including UK EHRs),6-9
detailed guidance on how to apply the hd-PS outside US claims data
is lacking. Important differences between data sources mean that
careful consideration is needed when implementing hd-PS principles
to ensure source-specific characteristics are handled appropriately.
We propose a series of modifications to the hd-PS that aim to
characterise key features of UK EHRs whilst adhering to the underly-
ing principles.5,6
2 | PROPENSITY SCORES
The PS is the conditional probability of being treated given a set of
observed covariates.10-12
PSs model the treatment allocation process and therefore offer
advantages over multivariable analysis in EHRs, since investigators are
forced to consider indications for treatment use and can convert large
amounts of confounder information into a single number.4
At a particular value of the PS, the distribution of observed
covariates is balanced between treated and untreated individuals, all-
owing consistent estimation of treatment effects, assuming all con-
founders are included in the model.13
3 | DESCRIPTION OF THE hd-PS
APPROACH AND UNDERLYING PRINCIPLES
3.1 | Preliminary steps
Demographics (d) and clinical factors believed to be important con-
founders (l) are forced into the PS model.5 A baseline time-window
for assessing patient confounder information is established (often
1 year before study entry date).
3.2 | Identification of most relevant covariates
Relevant information in the database is separated into p dimensions.5
The underlying principle is that each dimension should represent a dif-
ferent aspect of care relevant to the healthcare system under
investigation (principle 1). For example, in US claims data, it is typical
to separate information pertaining to diagnoses, procedures and
prescribing.5
Healthcare databases typically store information in the form of
thousands of discrete codes which vary by database. To avoid spar-
sity, information is often grouped at a granularity level set by the
investigator that captures related aspects of health status and care
(principle 2). We illustrate this using an example from the International
Classification of Diseases (ICD-10).14 The ICD-10 coding system is
hierarchical meaning that all information pertaining to one concept,
for example type 2 diabetes mellitus (T2DM), begins with the same
3-character code (E11 for T2DM).
Code groups are ranked by prevalence and investigators pre-
specify a number to be selected from each dimension.5
Code frequency is then assessed for each individual; measuring
the recurrence of identified codes in the baseline time-window. This
is summarised by three indicator variables:
Once: Code is recorded ≥ once.
Sporadic: Code is recorded ≥ the median
Frequent: Code is recorded ≥ the 75th percentile
This classification assumes that frequency of recording relates to
the importance of a code as a descriptor a patient's health status (prin-
ciple 3).
3.3 | Prioritisation
The steps so far generate a large pool of potential confounders.
Attempting to include all of these variables in the PS model would
often lead to concerns of overfitting therefore a variable selection
step is necessary to ensure statistical stability.
KEY POINTS
1. High-dimensional propensity score (hd-PS) approaches
are a popular method for confounder adjustment in
healthcare databases.
2. Whilst the performance of hd-PS is well established in
US claims data, there is a lack of guidance for applying
hd-PS principles in other settings.
3. We propose modifications to better tailor the hd-PS to
UK electronic health records and apply these to a recent
cohort study where results strongly suggested residual
confounding.
4. The modified hd-PS achieved results closer to those
obtained by a randomised controlled trial.
5. We have demonstrated that hd-PS approaches can be
usefully applied in UK electronic health records to
achieve improved confounder adjustment.
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The hd-PS uses the Bross formula to prioritise covariates across
dimensions by their potential to bias the treatment-outcome relation-
ship.5,15,16 This has three components. Firstly, it takes the confounded
apparent relative risk (ARR) for a particular binary covariate as a func-
tion of the relative risk (RR) in the absence of confounding by this
covariate. Secondly, the imbalance in prevalence amongst the exposed
(PC1) and unexposed (PC0) patients. Thirdly, the independent associa-
tion between a confounder and the study outcome (RRCD):
ARR=RR× biasM
where biasM =
PC1 RRCD−1ð Þ+1
PC0 RRCD−1ð Þ+1for all RRCD:
Each dimension is sorted in descending order by the magnitude
of jlog(biasM)j. This bias term takes a larger value the greater the
potential a covariate has to bias the relationship of interest. Therefore,
the top k empirical covariates are included in the PS. Typically several
hundred covariates are selected.
3.4 | Estimation of the hd-PS
The selected empirical covariates are added to the predefined vari-
ables before estimating the PS. Traditional PS methods are then used
to estimate the treatment effect.12 The final principle is that after
accounting for the top k empirically selected covariates, residual con-
founding effects are assumed to be negligible (principle 4).
4 | PROPOSED IMPLEMENTATION OF hd-
PS PRINCIPLES TO UK EHRS
In this section, issues surrounding the translation of hd-PS principles
to UK EHRs are discussed alongside our proposed modifications
(summarised in Figure 1).
4.1 | Principle 1: Identification of dimensions
There are important differences between insurance claims and EHR
data in terms of data availability, structure and the reasons for data
recording.17,18 This necessitated the identification of clinically rele-
vant dimensions based on patient contact with primary care services
in the UK. Since previous applications of hd-PS in UK EHRs have not
reached a consensus about what these dimensions should be, we
drew on general practitioner (GP) experience within our research
team.9,19 We proposed three dimensions separating clinical, referral
and prescription information (summarised in Table 1).
4.2 | Principle 2: Code granularity
Data in the clinical and referral dimension are recorded using the Read
code system.20 Read codes are less structured than coding systems
used in claims databases (eg, ICD-1014). Consequently, the Read cod-
ing system does not fully capture distinct concepts at any level of
granularity. For example, whilst the Read code 1434.00 relates to
F IGURE 1 Flowchart depicting hd-PS steps, underlying principles and adaptations for translating to UK electronic health records. GP, general
practitioner; hd-PS, high-dimensional propensity score; ICD-10, International Classification of Disease; T2DM, type 2 diabetes mellitus
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history of diabetes mellitus, grouping codes at the three-digit level
(eg, 143) would capture concepts in addition to diabetes such as
codes relating to thyroid disorder. Therefore, two codes with the
same three-digit Read code may capture disparate clinical concepts,
whereas conversely, two codes capturing similar concepts may have
different three-digit Read codes.
A manual solution to group all Read codes at a level capturing dis-
tinct medical concepts is not practical, therefore we mapped Read
codes to the ICD-10 coding system. This was achieved using cross
maps developed by NHS Digital21 and allowed replication of the
approach taken by Schneeweiss et al,5 which hierarchically grouped
distinct medical concepts at a certain granularity level.
For the prescription dimension the British National Formulary
(BNF) coding system is used. We classified prescriptions at the BNF
paragraph level which typically groups prescriptions by indication
rather than mechanism of action.22
4.3 | Principle 3: Code recurrence
Code frequency is assessed by the hd-PS to provide an indicator of a
patient's underlying health.5 In claims data all relevant information is
recorded at each instance a claim is completed which leads to an
intrinsic link between disease severity and code frequency.
EHRs exist for clinical record keeping which means that such a
link is harder to discern since all relevant information will not neces-
sarily be recorded at each consultation. Frequency of recording is
instead likely to be a function of several factors including severity of
illness, frequency of consultation and GP preference.
We classified the frequency of codes in a pre-specified baseline
time-window, 1 year prior to study entry. Recognising the variability
in recording we replaced the “Once” indicator with an “Ever” indicator
which captured whether a code had been recorded during a patient's
entire history. The remaining frequency indicators were assessed dur-
ing the baseline time-window.
We hypothesised that the degree to which information is
recorded at each consultation was likely to vary by dimension, with
more complete recording likely in the prescription and referral dimen-
sions. However, in the clinical dimension relevant information is often
not re-recorded at each consultation. For example, a patient receiving
prescriptions relating to a diagnosis of T2DM will have this diagnosis
recorded but not necessarily at each relevant consultation.
To investigate whether this information was likely to be over-
looked when assessing information in a narrow time-window we
extended the baseline time-window for the Clinical dimension.
Acknowledging the fact that patients will have varying lengths of
baseline information available we classified the frequency of codes by
assessing rates in instead of counts. We used three indicators to clas-
sify our revised frequency assessment (see Figure 1 for full definition).
4.4 | Principle 4: Selected number of variables
The capacity of the hd-PS to control for confounding can be sensitive
to the number of covariates selected.23,24 Whilst in claims data inves-
tigators typically specify 500 empirical covariates it is unclear if this is
appropriate in UK EHRs. We investigated the impact of selecting
100, 250, 500 and 750 covariates.
5 | APPLICATION TO EXAMPLE IN CPRD
5.1 | Data
The Clinical Practice Research Datalink (CPRD) is a de-identified pri-
mary care database broadly representative of patients registered at
GPs in the UK. It includes data pertaining to prescribing, diagnosis,
referrals and some lifestyle factors for approximately 9% of the UK
population.20
A recent cohort study using the CPRD linked with the Myocardial
Ischaemia National Audit Project (MINAP) investigated the combined
use of proton pump inhibitors (PPI) with clopidogrel and aspirin. A
possible interaction whereby PPIs may reduce the conversion of
clopidogrel to its active metabolite had been suggested, raising con-
cerns that combined use may lead to a reduction in clopidogrel effec-
tiveness and an increased risk of vascular events. The cohort analysis
found that combined use was indeed associated with an increased risk
of myocardial infarction (MI).3
The pattern of associations found strongly suggested that residual
confounding between patients may have explained the results as they
were not specific to MI and were found for both strong and weak
inhibitors of cytochrome P450 3A4 (the mechanism proposed for the
drug interaction). Furthermore, a self-controlled case series (SCCS)
analysis25 conducted on the same data found no evidence of
increased risk.
The authors concluded that the results from the cohort study
reflect confounding in the cohort estimate. In addition, unconfounded
studies based on genetic instrumental variable approaches using
genetic effects on drug metabolism pathways also suggested no evi-
dence of increased risk.26 A randomised double-blind trial has
TABLE 1 Summary of dimensions for UK electronic health
recordss
Dimension Information included Health status and care
Clinical Diagnoses, signs and
symptomsa
Indicates underlying
health of patient and
frequency of contact
with healthcare system
Referral Referrals to specialists Indicates escalation in
care or investigation
Prescriptions Drug prescriptions
issued in primary
care
Frequency and patterns
of drug usage
aThe clinical dimension also contains information relating to administrative
codes or references to measurements that occurred without results.
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subsequently also suggested a lack of clinical effect of PPIs on MI risk,
when used in combination with clopidogrel (HR = 0.92; 95% CI: 0.44-
1.90).27
5.2 | Design
We summarise the original study design conducted by Douglas et al.3
Patients had to be present in the CPRD with at least 12 months of
prior registration before first prescription for clopidogrel. Study entry
was defined as the latest of first recorded clopidogrel prescription in
combination with aspirin or 1 January 2003. Patients were censored
at the earliest of stopping treatment for aspirin or clopidogrel, death,
transferring out of the practice, last data collection date for the prac-
tice, 31 July 2009 or an occurrence of MI. Exposure was defined as
any prescription for a PPI. We focus on the incident MI outcome
which was ascertained using the MINAP database.
5.3 | Statistical analysis
The original study analysed the hazard ratio (HR) for the association
between PPI treatment and MI using Cox models, adjusting for
14 selected confounders. Missing data for body mass index, smoking
and alcohol consumption were handled using missing categories.
These conditions were applied consistently across all analyses.
We reanalysed the original data taking an intent-to-treat
approach that classified patients according to original exposure status
and incorporated baseline confounder information using PSs. We esti-
mated the PS using multivariable logistic regression to model the rela-
tionship between treatment and potential confounders. Inverse
probability of treatment weights (IPTW) were calculated from the PS
which essentially constructs two synthetic samples representing the
scenarios in which everyone had been treated and everyone had been
untreated.11 A weighted Cox model incorporating the IPTWs was
used to model the outcome.
Unless otherwise stated, all hd-PS analyses defined the three
aforementioned dimensions and assessed patient confounder infor-
mation recorded in the year prior to cohort entry. The top 200 most
prevalent codes were selected from each dimension and
500 covariates were included in the PS model.
We performed a standard hd-PS analysis which implemented the
algorithm using Read codes (classified at three-character Read code
granularity) for the clinical and referral dimensions. All Read codes
were included regardless of whether they map to ICD-10 to represent
the default position of applying the method wholesale to the coded
data in these dimensions. We then applied our modifications: mapping
the clinical and referral dimensions to ICD-10 and extending the fre-
quency assessment.
A sensitivity analysis extended the baseline time-window to
3 and 5 years for the Clinical dimension. We also investigated the
impact of selecting 100, 250 and 750 covariates on confounding
control.
All HR results are presented with 95% confidence intervals in
parentheses. Analyses were conducted using Stata 14.28
6 | RESULTS
Demographics and clinical characteristics for the cohort study are
summarised in Table 2. Twenty-four thousand four hundred and
seventy-one patients took clopidogrel, of whom 9111 were pre-
scribed a PPI. Of PPI users, 313 (3.4%) had an incident MI vs
421 (2.7%) in the non-users. Users of PPIs were older and were more
likely to have had a history of cancer, diabetes or peripheral vascular
disease compared to non-users (Table 2).
TABLE 2 Baseline characteristics by proton pump inhibitor status
amongst clopidogrel and aspirin users
Clopidogrel and aspirin users
No PPI PPI
N = 15 360 N = 9111
Demographics N (%) N (%)
Median age (years) 68.9 71.1
Sex
Male 10 007 (65.1) 5323 (58.4)
Body mass index (kg/m2)
<20 480 (3.1) 429 (4.7)
20-25 3987 (26.0) 2339 (25.7)
>25 10 004 (65.1) 5809 (63.8)
Missing 889 (5.8) 534 (5.9)
Smoking status
Non-smoker 4781 (31.1) 2780 (30.5)
Current 2760 (18.0) 1503 (16.5)
Ex-smoker 7777 (50.6) 4799 (52.7)
Missing 42 (0.3) 29 (0.3)
Alcohol status
Non-drinker 1528 (9.9) 1080 (11.9)
Ex-drinker 938 (6.1) 687 (7.5)
Amount not specified 399 (2.6) 254 (2.8)
<2 units/d 3060 (19.9) 1908 (20.9)
3–6 units/day 7488 (48.8) 4106 (45.1)
>6 units/d 1180 (7.7) 606 (6.7)
Status unknown 767 (5.0) 470 (5.2)
History of
Diabetes 4404 (28.7) 3090 (33.9)
Peripheral vascular disease 1629 (10.6) 1095 (12.0)
Coronary heart disease 12 198 (79.4) 7292 (80.0)
Ischaemic stroke 1571 (10.2) 954 (10.5)
Cancer 2038 (13.3) 1381 (15.2)
Abbreviation: PPI, proton pump inhibitor.
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For the modified analyses, we mapped the clinical and referral
dimensions from Read code to ICD-10. A large number of Read codes
represent non-clinical information, for example, codes relating to
administrative procedures. Since the aim of the mapping procedure is
solely to capture clinically relevant information unmapped Read codes
were expected. Upon inspection, the resulting unmapped codes could
generally be categorised as either administrative information (eg, a let-
ter), an indicator of a completed test without the result (eg, “blood
pressure reading was taken”) or coarse information we would typically
include more granularly in the pre-defined covariates (eg, broad
smoking terms). We include a sample of the most frequently occurring
unmapped Read codes in the Supporting Information.
Results for all analyses are presented in Table 3. Using the con-
founders originally identified by Douglas et al3 we obtained a HR for
the association between PPI use and MI of 1.17 (1.00-1.35).
Applying our modifications reduced the HR for the association
between PPI use and MI moving it towards a null result (Figure 2).
The fully modified hd-PS obtained an HR of 1.00 (0.78 to 1.28).
In sensitivity analyses, extending the baseline time-window for
the Clinical dimension lead to point estimates further from the null.
Varying the number of covariates did not meaningfully alter point esti-
mates. However, selecting fewer than 500 variables did improve the
precision of effect estimates (Table 3).
We investigated the estimated PS distributions by treatment
group obtained from investigator led and hd-PS analyses (Figure 3).
These distributions compare the characteristics of patients in the
populations under investigation. Compared to the investigator led
approach, the hd-PS exposed greater variation between the treatment
groups and captured extra predictors of prescribing which were also
causing confounding bias.
7 | DISCUSSION
In this study, we aimed to optimise the application of hd-PS principles
in UK EHR data. To investigate the potential of the hd-PS to account
for residual confounding we took a study where the authors were
confident the result obtained was subject to strong between patient
confounding. We aimed to get an improved point estimate, closer to
the expected null result, with similar precision to the original study.
After mapping Read to ICD-10 codes, changing the frequency assess-
ment, selecting 500 variables for inclusion and having a 1 year assess-
ment period for covariates, our final hd-PS model obtained an HR for
the association between MI and PPI use of 1.00 (0.78-1.28), com-
pared to 1.17 (1.00-1.35) using confounders selected using an investi-
gator led approach. Our modifications therefore achieved results
closer to those obtained by a randomised double-blind trial, although
the precision does not rule out results obtained from other studies.3,27
Sensitivity analyses suggested that extending the covariate assess-
ment period for the Clinical dimension to 3 or 5 years might not be
helpful in this setting.
The authors of the original study had suspected unmeasured
frailty or comorbidity severity was different between PPI users and
non-users. Here, we have demonstrated that differences between PPI
users and non-users are more apparent when using hd-PS than with
traditional approaches. This highlights the potential for hd-PS
approaches to include proxies for influential but unmeasured informa-
tion regarding a patient's underlying health status.
Our adaptations aimed to tailor the hd-PS to UK EHRs and should
be considered when applying the hd-PS in UK EHR data. The mapping
of clinical and referral information to ICD-10 allows for the identifica-
tion of homogeneous clinically meaningful proxies to be included in
the hd-PS, although we acknowledge that information contained in
F IGURE 2 Empirical performance of
hd-PS across our implemented
adaptations. hd-PS, high-dimensional
propensity score; ICD-10, International
Classification of Disease
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the unmapped codes is lost in this process. The inclusion of an Ever
category to the frequency assessment of the hd-PS also more accu-
rately captures recording practice in EHRs. Selecting 500 variables for
inclusion in the final hd-PS model performed well, however selecting
fewer variables obtained a very similar result with improved precision.
The framework we have built could also be extended to include labo-
ratory test results and free text information, the latter of which has
been previously explored.6
Whilst there have been several developments to the hd-PS since
its inception,6 there has been little exploration of how to translate the
algorithm beyond claims data. Much of this development work for
hd-PS has been focussed on demonstrating it obtains known associa-
tions, such as the effect of non-steroidal anti-inflammatory drugs on
the risk of gastrointestinal bleed.5,9,24,29 However, these results have
also been obtained through traditional methods of confounder adjust-
ment. In the case study we present, a hd-PS approach has removed a
known confounded association discovered using traditional methods.
Future applications of the hd-PS in this context will benefit from
updates to the cross-map between Read and ICD-10. In the literature
accompanying these cross-maps NHS Digital state that not every con-
cept in one coding system can or should be represented in another.21
NHS Digital's intention was to map clinically meaningful terms only,
and it was reassuring to observe that the majority of unmapped Read
codes were clinically uninformative and would typically be discarded
in an investigator analysis (see Supporting Information).
When calculating the SEs for treatment effects we have ignored
variable selection or estimation of the PS. Theoretically, this is likely to
result in narrower confidence intervals,30 although the practical conse-
quences are yet to be fully explored. We obtained a bias-corrected
bootstrap 95% CI based on 1000 replications for our final model of
0.70 to 1.30 (final model: [HR = 1.00; 95% CI: 0.78-1.28]).
Our results highlight the potential benefit of employing hd-PS
approaches in EHR studies, especially to overcome intractable con-
founding. However, the hd-PS is not a panacea and we acknowl-
edge that in studies where the confounding structure is relatively
simple, the robustness of results is unlikely to differ between tradi-
tional and hd-PS methods. We recognise the need for further explo-
ration of the hd-PS in this setting, via both controlled conditions
and case studies. One outstanding issue surrounds the transparency
of reporting when using hd-PS approaches and there is a need for
tools to better communicate proxies included in the final hd-PS
model.
This study has shown that the application of hd-PS methods out-
side the context of claims data requires careful consideration of how
to optimally apply hd-PS principles. By adapting hd-PS principles to
the UK EHR setting we have demonstrated the potential for hd-PS to
improve confounder adjustment in EHRs.
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